Is BMY stock a Buy, Sell, or Hold?

Based on our analysis, BMY is currently a WAIT with low confidence. 📊 MIXED SIGNALS: BMY shows conflicting indicators. Wait for confirmation before entering.

What is the fair value of BMY stock?

Our analysis estimates the fair value range for BMY to be between $64.16 and $67.17. The current price is $63.64.

What is the analyst price target for BMY?

The average Wall Street analyst price target for BMY is $66.21. This implies a potential upside of 4.0% from current levels.

Bristol-Myers Squibb (BMY) Stock: Buy, Sell, or Hold?

BMY - Bristol-Myers Squibb Co.

PHARMACEUTICAL PREPARATIONS

$63.64

-0.11 (-0.17%) ▼

5d: -6.54%

30d: -0.09%

90d: +11.85%

WAIT

LOW Confidence

Protect Your BMY Gains

Analysis Updated: Sep 11, 2026 12:00 AM ET

Earnings: Oct 29, 2026

Smart Money Accumulation

Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →

Signal fired Sep 4, 2026 at $66.82 · last confirmed Sep 10, 2026

Strength: 9.0/10

Get Alerted When BMY Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 MIXED SIGNALS: BMY shows conflicting indicators. Wait for confirmation before entering.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: -5.6%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$59.67

Based on -0.8% avg growth

INTRINSIC VALUE TODAY

$37.05

Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.5x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: BMY is currently trading at $63.64, which is considered oversold relative to its 30-day fair value range of $64.16 to $67.17. The stock's valuation (Forward PE: 9.7) is in line with its historical norms (9.5). At these levels, the market is pricing in 0.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.

Technical Outlook: Technically, BMY is in a strong uptrend. The price is currently testing key support at $63.27. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: BMY scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position OVERSOLD

Historical Trading Range $64.16 - $67.17

Company Quality Score 34/100 (SELL)

Volume Confirmation HIGH

Confidence Score 53.3%

Protect Your Profits

Holding BMY? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

BULLISH: Price oversold vs 30-day range
BEARISH: Weak technical setup (15/100)
BULLISH: High volume confirmation
NEUTRAL: Near Wall St target ($66.21)
NEUTRAL: Market pricing in 0.7% annual earnings growth - fairly valued
WARNING: Composite score 34/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $64.16 - $67.17

Current vs Trading Range OVERSOLD

Support & Resistance Levels

Support Level $63.27

Resistance Level $68.24

Current Trend Strong Uptrend

Technical data as of Sep 11, 2026

Fundamental Context

Forward P/E (Next Year Est.) 9.70

Wall Street Target $66.21 (+4.0%)

Revenue Growth (YoY) 5.7%

Earnings Growth (YoY) 153.1%

Profit Margin 18.9%

Valuation Premium vs History +0.7% premium

PE vs Historical 9.7 vs 9.5 FAIR

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): +0.7% (market-implied from PE analysis)

1-Year Target $64.09 (+1%)

2-Year Target $64.53 (+1%)

3-Year Target $64.99 (+2%)

3-Yr Target (if PE normalizes) (PE: 10→10) PE COMPRESSION $63.62 (0%)

Earnings growth offset by PE compression

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 20.2, Growth: -5.6%) $111.17 (+75%)

Base: (SPY PE: 9.7, Growth: -5.6%) $53.49 (-16%)

Bear: (PE: 8.2, Growth: -5.6%) $45.47 (-29%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (10x PE) as earnings recover.

Trailing PE: 14.04 | Current EPS (TTM): $4.54

Bull Case $101.30 (+59%)

Analyst growth 44.4%, PE expands to 15.5

Base Case $92.09 (+45%)

Market implied 44.4%, PE stable at 14.0

Bear Case $43.35 (-32%)

Severe decline -20.0%, PE contracts to 11.9

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: September 12, 2026 12:05 PM ET
Data refreshes hourly during market hours. Next update: 1:05 PM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is BMY showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

INSIDERS SELLING

Recent Transactions

David V Elkins SELL 30000 shares 2026-04-01

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for BMY.

Create Free Account

Already have an account? Log In

Featured in Portfolios

BMY is a key holding in these high-performance investment strategies.

Healthcare Giants Sector • +15.9% Return

View All Strategies

Top Rated Drug Manufacturers - General Stocks

Top-rated stocks in Drug Manufacturers - General by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
LLY Eli Lilly and Company	STRONG BUY 31 analysts	$1316	47 HOLD
GILD Gilead Sciences Inc	BUY 30 analysts	$157	44 HOLD
ABBV AbbVie Inc	BUY 28 analysts	$277	53 HOLD
BIIB Biogen Inc	HOLD 37 analysts	$237	47 HOLD
AMGN Amgen Inc	HOLD 32 analysts	$390	43 HOLD

LLY Eli Lilly and Com…

47 HOLD

GILD Gilead Sciences I…

Advanced BMY Option Strategies

Professional options setups generated by AI based on today's BMY price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for BMY

BMY Technical Chart BMY Price Prediction BMY Earnings Date BMY Investment Advisor BMY Fair Price Analyzer BMY Options Advisor BMY Options Chain BMY Options Analysis BMY Competitors

Compare BMY with Peers

BMY vs MRK
Which one to buy?

BMY vs ABT
Which one to buy?

BMY vs LLY
Which one to buy?

BMY vs ABBV
Which one to buy?

BMY vs AMGN
Which one to buy?

PTCT vs BMY
Winner: BMY

DOW vs BMY
Winner: BMY

LLY vs BMY
Winner: LLY

CALC vs BMY

BMY vs NGNE

Create New Comparison View All Competitors

Tradestie